

Radicava™ (edaravone) – New orphan drug approval

- On May 5, 2017, the [FDA announced](#) the approval of Mitsubishi Tanabe Pharma Corporation's [Radicava \(edaravone\)](#) injection for the treatment of amyotrophic lateral sclerosis (ALS).
 - [MT Pharma America](#) is a subsidiary of Mitsubishi Tanabe Pharma Corporation.
- ALS, commonly referred to as Lou Gehrig's disease, is a rare disease that attacks and kills the nerve cells of muscles involved in movements such as chewing, walking, breathing, and talking. ALS is progressive and leads to paralysis.
- The [Centers for Disease Control and Prevention](#) estimates that approximately 12,000 – 15,000 Americans have ALS. Most people with ALS die from respiratory failure, usually within three to five years from when the symptoms first appear.
- The mechanism by which Radicava exerts its therapeutic effect in patients with ALS is unknown.
- The efficacy of Radicava was based on data from a 6 month, placebo-controlled clinical study of 137 patients with ALS. The primary efficacy endpoint was a comparison of change between treatment arms in the ALS functional rating scale – revised (ALSFRS-R) from baseline to week 24. Higher ALSFRS-R scores represent greater functional ability.
 - The decline in ALSFRS-R scores from baseline was significantly less in Radicava-treated patients vs. placebo-treated patients (-5.01 ± 0.64 vs. -7.50 ± 0.66 , respectively, $p = 0.0013$; treatment difference: 2.49, 95% CI: 0.99, 3.98).
- Warnings and precautions of Radicava include hypersensitivity reactions and sulfite allergic reactions.
- The most common adverse reactions ($\geq 10\%$ and greater than placebo) with Radicava use were contusion, gait disturbance, and headache.
- The recommended dosage of Radicava is 60 mg administered as an intravenous (IV) infusion over 60 minutes as follows:
 - Initial treatment cycle: daily dosing for 14 days, followed by a 14-day drug free period
 - Subsequent treatment cycles: daily dosing for 10 days out of 14-day periods, followed by 14-day drug-free periods
- MT Pharma America created Searchlight Support, a patient access program for people with ALS who are prescribed Radicava. Searchlight Support will provide personal case management, reimbursement support, and 24/7 clinical support.

- The cost of Radicava is \$1,086 per infusion (\$145,524 per year).
- MT Pharma America plans to launch Radicava in August 2017. Radicava will be available as a 30 mg/100 mL (0.3 mg/mL) solution for IV infusion.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at optum.com.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.